KOBAYASHI PHARMACEUTICAL CO., LTD. a drug manufacturer. The Company operates in three segments. The Domestic Household Products Manufacturing and Sales segment and Overseas Household Products Manufacturing and Sales segment offer health care, daily necessities, skin care and other products. The Mail Order segment involves in the mail order of dietary supplements, skin care products and others.

Employees

3,534

Sector

Personal Products

Calendar

28/10/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
13/09/24	5,423.00 ¥	-1.69%	367,500
12/09/24	5,516.00 ¥	+1.88%	364,800
11/09/24	5,414.00 ¥	-2.36%	412,400
10/09/24	5,545.00 ¥	+0.34%	314,000
09/09/24	5,526.00 ¥	-0.07%	444,500

Delayed Quote Japan Exchange, September 13, 2024 at 07:00 am

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

5,423.00JPY

Average target price

5,705.71JPY

Spread / Average Target

+5.21%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Market Closed - Japan Exchange Other stock markets 07:00:00 13/09/2024 BST			5-day change	1st Jan Change
5,423.00 ^JPY	-1.69%		-1.93%	-20.13%

07-23	Kobayashi Pharmaceutical Co., Ltd. Announces Management Changes	CI
06-24	Kobayashi Pharmaceutical Co., Ltd.(TSE:4967) dropped from S&P Japan Mid Cap 100	CI

Capitalization	403B 2.86B 218B	P/E ratio 2024 *	29.7x	P/E ratio 2025 *	22x
Enterprise value	425B 3.02B 230B	EV / Sales 2024 *	1.91x	EV / Sales 2025 *	1.8x
Free-Float	59.84%	Yield 2024 *	1.9%	Yield 2025 *	1.93%

Kobayashi Pharmaceutical Co., Ltd. Announces Management Changes	07-22	CI
Kobayashi Pharmaceutical Co., Ltd.(TSE:4967) dropped from S&P Japan Mid Cap 100	06-23	CI
Japan companies hog the spotlight as hedge funds tout their top Asia picks	05-24	RE
A second Kobayashi Pharma Japan factory inspected over deaths	03-31	RE
Kobayashi factory searched over deaths possibly linked to supplements	03-30	RE
Kobayashi Pharmaceutical Recalls 'Beni-Koji' Supplement Following Report of Death, Kidney Damage	03-27	MT
Tranche Update on Kobayashi Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 7, 2023.	11-08	CI
Kobayashi Pharmaceutical Co., Ltd's Equity Buyback announced on November 7, 2023, has closed with 1,924,600 shares, for ¥11,999.88 million.	11-07	CI
Kobayashi Pharmaceutical Co., Ltd. acquired Focus Consumer Healthcare, LLC.	06/10/23	CI
Kobayashi Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/05/23	CI
Organ Technologies Inc announced that it has received funding from Kobayashi Pharmaceutical Co., Ltd.	09/02/23	CI
Tranche Update on Kobayashi Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 1, 2022.	02/11/22	CI
Kobayashi Pharmaceutical Co., Ltd.'s Equity Buyback announced on November 1, 2022, has closed with 1,150,602 shares, representing 1.49% for ¥9,991.92 million.	01/11/22	CI

Japan companies hog the spotlight as hedge funds tout their top Asia picks	05-24	RE
UBS Adjusts Kobayashi Pharmaceutical's Price Target to 12,600 Yen From 13,100 Yen, Keeps at Buy	03/03/22	MT

Kobayashi Pharmaceutical Co., Ltd. Share Price

Equities

4967

JP3301100008

Personal Products

Valuation: Kobayashi Pharmaceutical Co., Ltd.

Chart: Kobayashi Pharmaceutical Co., Ltd.

Latest news: Kobayashi Pharmaceutical Co., Ltd.

Analysts' recommendations: Kobayashi Pharmaceutical Co., Ltd.

Press Releases: Kobayashi Pharmaceutical Co., Ltd.

News in other languages: Kobayashi Pharmaceutical Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Kobayashi Pharmaceutical Co., Ltd.

ETFs: Kobayashi Pharmaceutical Co., Ltd.

Other Personal Products

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly earnings, Rate of surprise

Kobayashi Pharma to exit red yeast rice business amid health scandal	08-08	AQ
Kobayashi Pharmaceutical : FY2024（January 1, 2024 - December 31, 2024）2Q Financial Statement	08-07	PU
Kobayashi Pharmaceutical : Financial Overview for Second Quarter of Fiscal 2024(Fiscal Year Ending December 31, 2024)	08-07	PU
UPDATE1: Kobayashi Pharma chairman, president resign over supplements scandal	07-23	AQ
Head of disgraced Japanese pharma company resigns	07-23	AQ

Razzia bei japanischem Pharma-Konzern nach Todesfällen	03-31
Scandale aux compléments alimentaires au Japon: deux nouveaux décès suspects	03-28
Bourses asiatiques: Tokyo soutenue par la chute du yen	03-27
Tokyo en hausse en matinée	03-27

1 day	-1.69%
1 week	-1.93%
Current month	-3.16%
1 month	-0.02%
3 months	-1.85%
6 months	-10.22%
Current year	-20.13%

Director	Title	Age	Since
Satoshi Yamane BRD	Director/Board Member	64	28/02/83
Noriaki Hirao IRC	Investor Relations Contact	-	-
Kenji Kohori SAM	Sales & Marketing	69	-

Name	Weight	AuM	1st Jan change	Investor Rating
NOMURA NEXT FUNDS TOPIX-17 RAW MATERIALS & CHEMICALS ETF - JPY	1.19%	11 M€	+3.37%
NEXT FUNDS MSCI JAPAN COUNTRY ESG LEADERS INDEX EXCHANGE TRADED FUND - JPY	0.21%	15 M€	+11.34%

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
KOBAYASHI PHARMACEUTICAL CO., LTD.	-1.69%	-1.93%	-23.05%	-40.60%	2.88B
PROCTER & GAMBLE COMPANY	+0.35%	-0.86%	+13.71%	+19.49%	408B
UNILEVER PLC	+0.26%	-0.92%	+22.46%	+23.54%	160B
COLGATE-PALMOLIVE COMPANY	-0.57%	-1.97%	+45.17%	+36.64%	86.89B
HINDUSTAN UNILEVER LIMITED	-0.66%	+3.36%	+17.06%	+5.36%	82.67B
KENVUE INC.	+1.34%	+2.32%	+8.29%	-	44.2B
BEIERSDORF	+0.16%	-0.82%	+4.06%	+20.19%	31.32B
ESTEE LAUDER	+0.43%	-3.36%	-44.51%	-74.60%	30.2B
ESSITY AB	+0.19%	+0.38%	+33.36%	+19.29%	21.7B
GODREJ CONSUMER PRODUCTS LIMITED	-1.46%	+3.31%	+48.59%	+33.00%	18.44B
Average	-0.16%	+0.18%	+12.51%	+4.70%	88.62B
Weighted average by Cap.	+0.15%	-0.31%	+17.18%	+17.38%

	2024 *	2025 *
Net sales	171B 1.21B 92.45B	180B 1.28B 97.64B
Net income	13.32B 94.58M 7.21B	18.35B 130M 9.93B
Net Debt	-77.23B -548M -41.8B	-77.94B -553M -42.18B